Treffert D A, Joranson D E
JAMA. 1983 Mar 18;249(11):1469-72.
The Controlled Substances Board evaluated the implementation of the National Cancer Institute (NCI) program in Wisconsin that distributes delta 9-tetrahydrocannabinol (delta 9-THC) to cancer chemotherapy patients with nausea and vomiting refractory to conventional antiemetic drugs. The board concluded that the distribution mechanism for delta 9-THC is appropriate and adequate in Wisconsin. The drug does relieve nausea and vomiting in some cancer chemotherapy patients, but adverse side effects are prevalent. Important questions about its safety and effectiveness remain and should be resolved through scientific research and within the existing framework for testing investigational drugs that are controlled substances. "Marijuana therapeutic research" legislation, similar to that passed in 32 states, was introduced in Wisconsin after implementation and evaluation of the NCI program, but failed to recognize the existing legal framework for approving new drugs and threatened to disrupt the NCI program. With assistance from the American Cancer Society, the State Medical Society, and volunteers and professionals in cancer research, the legislation was adapted to the existing legal and administrative framework.
药物管制局评估了美国国家癌症研究所（NCI）在威斯康星州开展的一项项目的实施情况，该项目向那些对传统止吐药物难治性恶心和呕吐的癌症化疗患者分发Δ⁹-四氢大麻酚（Δ⁹-THC）。该局得出结论，在威斯康星州，Δ⁹-THC的分发机制是恰当且充分的。该药物确实能缓解一些癌症化疗患者的恶心和呕吐，但不良副作用很普遍。关于其安全性和有效性的重要问题依然存在，应通过科学研究并在现有用于测试作为管制物质的研究性药物的框架内加以解决。在NCI项目实施和评估之后，威斯康星州引入了类似于32个州所通过的“大麻治疗研究”立法，但该立法没有认识到批准新药的现有法律框架，并有扰乱NCI项目的风险。在美国癌症协会、州医学协会以及癌症研究领域的志愿者和专业人员的协助下，该立法进行了调整以适应现有的法律和行政框架。
